Break Through Cancer launches a $15M multi-institute pediatric osteosarcoma research initiative   September 26, 2025 Vol.51 No.35 Break Through Cancer has launched the Defying Osteosarcoma TeamLab, an initiative that brings together more than 20 researchers from eight institutions in a coordinated, multi-year effort focused on improving pediatric osteosarcoma care. Read More at The Cancer Letter...

Continue reading

Can a virtual team of researchers break a 40-year logjam in this rare cancer? John Carroll August 25, 2025 When Mac Tichenor’s son Willie died of osteosarcoma at the age of 19 back in 2006, oncologists still relied on a decades-old chemo regimen called MAP — high-dose methotrexate, combined with doxorubicin and cisplatin. Typically, for young patients with the rare bone cancer, it staved off death for a while. Read More at Endpoints News...

Continue reading

Detecting minimal residual disease may be key to preventing ovarian cancer recurrence By Josh Friedman Fact checked by Heather Biele August 27, 2025 Key takeaways: Women who had minimal residual disease following first-line ovarian cancer treatment had significantly worse OS. Many women who appeared in remission had surgically- or ctDNA-detected minimal residual disease. Read More at Healio...

Continue reading

A New Approach to Undetectable Ovarian Cancer Author: Amir Jazaeri, MD Fact checked by: Sabrina Serani August 23, 2025 Amir Jazaeri, MD, of MD Anderson Cancer Center, provides an in-depth perspective on the complex challenges of treating ovarian cancer. He explains that a majority of patients are diagnosed with advanced-stage disease, meaning the cancer has already spread extensively throughout the abdomen and possibly to other parts of the body. Despite this initial widespread nature, a combination of radical surgery and six cycles of platinum-based chemotherapy is often highly effective, leading to a state of remission where patients are considered cancer-free. Read......

Continue reading

The Prognostic Value of Residual Disease in Ovarian Cancer Authors: Sabrina Serani & Amir Jazaeri, MD Fact checked by: Jason M. Broderick August 22, 2025 Key Takeaways SLL and ctDNA are effective in detecting MRD in ovarian cancer, surpassing conventional methods like CA 125 and CT scans. SLL provides access to MRD tissue, offering insights into chemoresistance and potential therapeutic targets. CtDNA is a promising early surrogate endpoint in clinical trials, allowing earlier assessment of treatment efficacy. Identifying high-risk patients through these methods enables earlier intervention with innovative and investigational therapies. Read More at Targeted Oncology...

Continue reading

Study Reveals Missed Opportunities for Surgical Prevention of Ovarian Cancer Author: Jason M. Broderick Fact checked by: Sabrina Serani August 15, 2025 Key Takeaways Concurrent salpingectomy during unrelated surgeries could prevent 25% of HGSC cases, highlighting missed opportunities in 23.7% of patients. Missed genetic testing and risk-reducing surgery occurred in 43.2% of women with a first-degree relative affected by HGSC. The study suggests a risk-assessment algorithm to prioritize salpingectomy and individualized counseling for patients with different risk profiles. Read More at Targeted Oncology...

Continue reading

Missed Opportunities to Prevent Ovarian Cancer During Unrelated Surgeries by Charles Bankhead, Senior Editor, MedPage Today August 14, 2025 • 4 min read Salpingectomy often omitted during surgery for permanent contraception, other procedures Key Takeaways Genetic susceptibility accounts for 20% of ovarian cancer risk, and risk-reducing bilateral salpingectomy remains the gold standard for prevention. In this study, about 24% of patients with high-grade serous ovarian cancer had missed opportunities for risk-reducing surgery before cancer diagnosis. Among the women with a first-degree family history of ovarian cancer, 43.2% had mutations that increased susceptibility to ovarian cancer. Read More at MedPage Today...

Continue reading

Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission August 04, 2025 Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies. Author: Russ Conroy Fact checked by: Roman Fabbricatore Read More at CancerNetwork...

Continue reading